Comparison between concentrations of amphotericin B in infected lung lesion and in uninfected lung tissue in a patient treated with liposomal amphotericin B (AmBisome)

International Journal of Infectious Diseases

Volumn 14, Issue SUPPL. 3, 2010, Pages

  Watanabe, Akira ^a,b   Matsumoto, Kana ^c   Igari, Hidetoshi ^a   Uesato, Masaya ^b   Yoshida, Shigetoshi ^b   Nakamura, Yasutaka ^a   Morita, Kunihiko ^c   Shibuya, Kazutoshi ^d   Matsubara, Hisahiro ^b   Yoshino, Ichiro ^b   Kamei, Katsuhiko ^a,b  

^a CHIBA UNIVERSITY HOSPITAL   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c DOSHISHA WOMEN'S COLLEGE OF LIBERAL ARTS   (Japan)

^d TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Liposomal amphotericin B; Pulmonary aspergillosis; Tissue concentration

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; FLUCYTOSINE; MICAFUNGIN; VORICONAZOLE;

ADULT; ARTICLE; ASPERGILLUS; BONE CANCER; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUNG ASPERGILLOSIS; LUNG CANCER; LUNG LOBECTOMY; LUNG PARENCHYMA; MALE;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLUS NIGER; HUMANS; LIPOSOMES; LUNG; MALE; MIDDLE AGED; PULMONARY ASPERGILLOSIS; TISSUE DISTRIBUTION;

EID: 77957371597     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2009.07.020     Document Type: Article

References (19)

1. Walsh T.J., Anaissie E.J., Denning D.W., Herbrecht R., Kontoyiannis D.P., Marr K.A., et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:327-360.
2. Lanternier F., Lortholary O. Liposomal amphotericin B: what is its role in 2008?. Clin Microbiol Infect 2008, 14(Suppl 4):71-83.
3. Heinemann V., Bosse D., Jehn U., Debus A., Wachholz K., Forst H., et al. Enhanced pulmonary accumulation of liposomal amphotericin B (AmBisome) in acute liver transplant failure. J Antimicrob Chemother 1997, 40:295-297.
4. Ellis M. New dosing strategies for liposomal amphotericin B in high-risk patients. Clin Microbiol Infect 2008, 14(Suppl 4):55-64.
5. Smith P.J., Olson J.A., Constable D., Schwartz J., Proffitt R.T., Adler-Moore J.P. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B. J Antimicrob Chemother 2007, 59:941-951.
6. Hanazawa R., Murayama S.Y., Yamaguchi H. In-situ detection of Aspergillus fumigatus. J Med Microbiol 2000, 49:285-290.
7. Takemoto K., Yamamoto Y., Ueda Y., Sumita Y., Yoshida K., Niki Y. Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis. J Antimicrob Chemother 2006, 57:724-731.
8. Vogelsinger H., Weiler S., Djanani A., Kountchev J., Bellmann-Weiler R., Wiedermann C.J., et al. Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. J Antimicrob Chemother 2006, 57:1153-1160.
9. Walsh T.J., Goodman J.L., Pappas P., Bekersky I., Buell D.N., Roden M., et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001, 45:3487-3496.
10. Paterson P.J., Seaton S., Prentice H.G., Kibbler C.C. Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B. J Antimicrob Chemother 2003, 52:873-876.
11. Collette N., van der Auwera P., Lopez A.P., Heymans C., Meunier F. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob Agents Chemother 1989, 33:362-368.
12. Janknegt R., de Marie S., Bakker-Woudenberg I.A., Crommelin D.J. Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clin Pharmacokinet 1992, 23:279-291.
13. Adler-Moore J. AmBisome targeting to fungal infections. Bone Marrow Transplant 1994, 14(Suppl 5):S3-7.
14. Lopez-Berestein G., Rosenblum M.G., Mehta R. Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans. Cancer Drug Deliv 1984, 1:199-205.
15. Andes D., Safdar N., Marchillo K., Conklin R. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob Agents Chemother 2006, 50:674-684.
16. Christiansen K.J., Bernard E.M., Gold J.W., Armstrong D. Distribution and activity of amphotericin B in humans. J Infect Dis 1985, 152:1037-1043.
17. Collette N., Van der Auwera P., Meunier F., Lambert C., Sculier J.P., Coune A. Tissue distribution and bioactivity of amphotericin B administered in liposomes to cancer patients. J Antimicrob Chemother 1991, 27:535-548.
18. Ringdén O., Meunier F., Tollemar J., Ricci P., Tura S., Kuse E., et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991, 28(Suppl B):73-82.
19. Demartini G., Lequaglie C., Brega Massone P.P., Scaglione F., Fraschini F. Penetration of amphotericin B in human lung tissue after single liposomal amphotericin B (AmBisome) infusion. J Chemother 2005, 17:82-85.